The company was founded with a mission to create targeted therapies for the treatment of the most aggressive types of brain cancer, based on the pioneering research of Dr. Santosh Kesari. With a team of experienced leaders in the pharmaceutical industry, Curtana is developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system, with a focus on glioblastoma and other brain cancers. Curtana has received a $7.6M grant from the Cancer Prevention and Research Institute of Texas, and current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, and other anonymous investors.